热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　腾盛博药-B（02137）逆市上涨21.77%，现报1.51港元，成交额2764.64万港元。

　　高盛认为，中国政府近年来推出的一系列创新激励政策，正在为生物科技企业创造更加有利的发展环境。2024年《全链条支持创新药发展实施方案》的出台，进一步优化了药品审评审批、医保支付、投融资等政策环境，为创新药企业提供了强有力的政策保障。高盛指出，中国作为创新来源地的地位日益凸显，并将在全球范围内获得更广泛的认可。该行持续看好中国的领先生物科技公司，预计数家头部企业将在强劲的销售增长和严格的支出控制下不断提高运营效率，从而在2025/26年实现收支平衡。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.